Roche to acquire US-based Poseida <a href="https://laohu8.com/S/LENZ">Therapeutics</a> BERLIN, Nov 26 (Reuters) - Roche ROG.S will acquire California-based biopharmafirm Poseida Therapeutics PSTX.O for $9 per share at closing, for a total equity value of $1 billion, the Swiss company said on Tuesday.
Stockholders will also receive a non-tradeable contingent value right $(CVR)$ for $4 per share, representing a total deal value of up to approximately $1.5 billion, said the company.
The transaction is expected to close in the first quarter of 2025.
(Writing by Miranda Murray; Editing by Tom Hogue)
((Miranda.Murray@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments